Clinical Trials Browser

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT03590574 2026-03-16

Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma

Phase 1/2 Terminated

20 enrolled 34 charts

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Genitourinary

Prostatic Neoplasms

NCT03953326 2026-02-27

HeartPhone Cancer Survivors Trial 2019

Phase 1/2 Terminated

2 enrolled 6 charts

BreastLymphoidOther hematologic neoplasm

Breast Neoplasms, Leukemia, Lymphoma

NCT04362007 2026-02-25

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Phase 1/2 Terminated

8 enrolled 11 charts

Lymphoid

Lymphoma, Recurrence

NCT02942264 2026-02-23

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Phase 1/2 Terminated

53 enrolled 22 charts

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Recurrence, Gliosarcoma

NCT05269160 2026-02-17

Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)

Phase 1/2 Terminated

3 enrolled 8 charts

Breast

Breast Neoplasms, Radiodermatitis

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03559049 2026-02-12

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Phase 1/2 Terminated

25 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04809467 2026-02-04

topMIND

Phase 1/2 Terminated

54 enrolled 23 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04913220 2026-02-04

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Phase 1/2 Terminated

46 enrolled 22 charts

Dermatologic

Melanoma

NCT04187404 2026-01-30

Spencer

Phase 1/2 Terminated

70 enrolled 20 charts

CNSEndocrine

Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT05590377 2026-01-30

iinnovate-3

Phase 1/2 Terminated

15 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT03215030 2026-01-29

iinnovate-1

Phase 1/2 Terminated

272 enrolled 67 charts

Plasma cell

Multiple Myeloma

NCT03553602 2026-01-29

BEACON

Phase 1/2 Terminated

3 enrolled 7 charts

Genitourinary

Prostatic Neoplasms

NCT04157517 2026-01-29

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

45 enrolled 44 charts

Dermatologic

Melanoma, Neoplasms

NCT04856189 2026-01-29

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

4 enrolled 8 charts

Genitourinary

Carcinoma, Transitional Cell

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04379518 2026-01-13

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Phase 1/2 Terminated

4 enrolled 30 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Phase 1/2 Terminated

34 enrolled 44 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04240002 2026-01-05

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

9 enrolled 21 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1/2 Terminated

75 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05313009 2025-12-16

Tarlox and Sotorasib in Patients With KRAS G12C Mutations

Phase 1/2 Terminated

5 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05918055 2025-12-02

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Phase 1/2 Terminated

3 enrolled 9 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast

Breast Neoplasms

NCT02706353 2025-11-21

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Phase 1/2 Terminated

34 enrolled 18 charts

Dermatologic

Melanoma

NCT05525286 2025-11-17

CLAUDIO-01

Phase 1/2 Terminated

31 enrolled 34 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT03519178 2025-11-14

A Study of PF-06873600 in People With Cancer

Phase 1/2 Terminated

155 enrolled 44 charts

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT04106492 2025-11-14

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

Phase 1/2 Terminated

53 enrolled 23 charts

GynecologicHead & NeckSarcomaThoracic

Head and Neck Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma, Uterine Neoplasms

NCT05194735 2025-11-10

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Phase 1/2 Terminated

8 enrolled 12 charts

GastrointestinalGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05617040 2025-11-10

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Phase 1/2 Terminated

22 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

116 enrolled 36 charts

MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT03837509 2025-11-04

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

15 enrolled 15 charts

Plasma cell

Multiple Myeloma, Recurrence

Clinical Trials

Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

BM7PE

Morpheus Lung

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Mirdametinib + BGB-3245 in Advanced Solid Tumors

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

CPIT001

CMP-001 for Relapsed and Refractory Lymphoma

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma

CELLO-1

HeartPhone Cancer Survivors Trial 2019

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

topMIND

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Spencer

iinnovate-3

iinnovate-1

BEACON

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Tarlox and Sotorasib in Patients With KRAS G12C Mutations

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

AMEERA-1

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

CLAUDIO-01

A Study of PF-06873600 in People With Cancer

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma